SEC Form 4 · accession 0001808343-26-000002
Immunome Inc. · IMNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isaac Barchas
Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 12, 2026 · 5:48 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001472012
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1,F2 | $18.16 | Jun 10, 2026 | A | 9,897 | A | — | Jun 9, 2036 | Common Stock | 9,897 | 9,897 | D |
Explanation of responses
- F1Mr. Barchas has agreed to receive and hold for the benefit of Arsenal Bridge Ventures any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Barchas disclaims beneficial ownership of, and all right, title and interest in, the reported securities.
- F2The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to Mr. Barchas' continuous service with the Company on each respective vesting date.